Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma

ConclusionPatients with a suspected papillary craniopharyngioma can be challenged with dabrafenib as a potentially effective diagnostic and therapeutic strategy, given that rapid regression with dabrafenib is only observed in tumors harboring aBRAF V600 mutation. Further work is needed to explore the optimal regimen and dose of the targeted therapy.
Source: Pituitary - Category: Endocrinology Source Type: research